Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 2
Results: 20
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 493, doi. 10.1007/s00262-022-03267-5
- By:
- Publication type:
- Article
Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 461, doi. 10.1007/s00262-022-03266-6
- By:
- Publication type:
- Article
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 427, doi. 10.1007/s00262-022-03265-7
- By:
- Publication type:
- Article
Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 515, doi. 10.1007/s00262-022-03264-8
- By:
- Publication type:
- Article
Single-cell analysis of peripheral CD8<sup>+</sup> T cell responses in patients receiving checkpoint blockade immunotherapy for cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 397, doi. 10.1007/s00262-022-03263-9
- By:
- Publication type:
- Article
Bloody pericardial effusion during chemotherapy with immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 523, doi. 10.1007/s00262-022-03261-x
- By:
- Publication type:
- Article
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 277, doi. 10.1007/s00262-022-03260-y
- By:
- Publication type:
- Article
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 437, doi. 10.1007/s00262-022-03259-5
- By:
- Publication type:
- Article
Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 371, doi. 10.1007/s00262-022-03258-6
- By:
- Publication type:
- Article
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
High abundance of Lachnospiraceae in the human gut microbiome is related to high immunoscores in advanced colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 315, doi. 10.1007/s00262-022-03256-8
- By:
- Publication type:
- Article
Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 385, doi. 10.1007/s00262-022-03254-w
- By:
- Publication type:
- Article
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 475, doi. 10.1007/s00262-022-03253-x
- By:
- Publication type:
- Article
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 339, doi. 10.1007/s00262-022-03252-y
- By:
- Publication type:
- Article
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 449, doi. 10.1007/s00262-022-03251-z
- By:
- Publication type:
- Article
A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 351, doi. 10.1007/s00262-022-03255-9
- By:
- Publication type:
- Article
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 287, doi. 10.1007/s00262-022-03245-x
- By:
- Publication type:
- Article
Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 327, doi. 10.1007/s00262-022-03241-1
- By:
- Publication type:
- Article
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 409, doi. 10.1007/s00262-022-03238-w
- By:
- Publication type:
- Article
Personalized tumor vaccine for pancreatic cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 301, doi. 10.1007/s00262-022-03237-x
- By:
- Publication type:
- Article